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Abstract The discovery of induced pluripotent stem cells
(iPSCs) and concurrent development of protocols for their
cell-type specific differentiation have revolutionized studies
of diseases and raised the possibility that personalized medi-
cine may be achievable. Realizing the full potential of iPSC
will require addressing the challenges inherent in obtaining
appropriate cells for millions of individuals while meeting the
regulatory requirements of delivering therapy and keeping
costs affordable. Critical to making PSC based cell therapy
widely accessible is determining which mode of cell collec-
tion, storage and distribution, will work. In this manuscript we
suggest that moderate sized bank where a diverse set of lines
carrying different combinations of commonly present HLA
alleles are banked and differentiated cells are made available
to matched recipients as need dictates may be a solution. We
discuss the issues related to developing such a bank and how it
could be constructed and propose a bank of selected HLA
phenotypes from carefully screened healthy individuals as a
solution to delivering personalized medicine.
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Using IPSC for Cell Based Therapy
The ability to harvest somatic cell from any individual and
reprogram them with high fidelity and reasonable efficiency
has lead to proposal of personalized medicine where either
autologous or HLAmatched tissue cells could be obtained and
then used to make iPSCs that are differentiated into the ap-
propriate required phenotype [1–3]. Several models of such
cell based therapy have been proposed [4]. One model is to
use autologous PSC-derived cell products or engineered PSC-
derived cells for cell replacement or as a vehicle for the
delivery of a payload such as an enzyme or drug. Like other
autologous cell therapies, the use of patient-specific PSCs will
bypass the issue of immune rejection. Alternatively, if HLA
matched banks of iPSCs are available, this “hybrid” model
will allow the selection and use of optimally-matched cells to
produce graft material that will only require limited immune
suppression [5–7].
The truly autologous model although ideal in principle
suffers from several practical disadvantages. Perhaps the most
important one is that it takes time to generate an iPSC line.
This time ranges in terms of weeks and months rather than
days. Performing the selection and characterization of a clone
as required by FDA regulations for all “more than minimally
processed cells based therapy” adds additional time to the
generation process as well as adding significantly to the cost
of therapy. Further autologous cells may carry gene defects
that will need to be corrected and thusmay require further time
to process, characterize and make available to the patient. This
may restrict the use of such autologous cells to only chronic
diseases where sufficient time is available to perform the
necessary processes and the benefits of the therapy are pro-
portionate to the cost of this process. The choice of such
autologous therapy may be further restricted if gene engineer-
ing is not sufficiently efficient or if the regulations require
additional testing of each subclone made [8–10].
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AHLAmatched bankmodel obviates some of these issues.
A pool of cells can be made based on allelic frequencies of
HLA phenotypes and standard HLA matching designs can be
used to give individuals a reasonable probability of obtaining
a match. Unlike other cells the IPSCs are a virtually infinite
supply so such a bank once set up would not be depleted by
demand. Current estimates are that a relatively small number
(in the hundreds) of lines carefully selected based on allelic
frequencies would be sufficient [5–7]. More importantly the
effort could be spread worldwide so that each group of indi-
vidual needed to contribute a small subset of lines making the
cost quite manageable. While the initial set-up would be
expensive [8, 9] the availability of an off the shelf product
that is rigorously tested and widely available would be much
easier for the regulatory authorities to grant approval for.
Equally important since carefully screened donors are selected
that are healthy and do not carry major susceptibility genes
one can reduce the need for genome editing as may be re-
quired in a true autologous transplant (see above).
It is important to point out that while such a model seems
attractive as compared to a truly autologousmodel it is still not
as cheap as having a allogeneic therapy where a single or two
or three cell lines are selected for their ability to grow and
differentiate into the required end product which can be used
for therapy. Proponents of such allogeneic therapy model have
argued that immune suppression may not be required in many
cases such as when cells are only required for a short time
period or when cells themselves are not immunogenic or when
cells are transplanted into immune privileged sites [11–13].
Investigators have noted as well that in the case where im-
mune suppression is required localized immune suppression
may be effective and in any case current matching and the
presence of minor antigen mismatches can be sufficient for
rejection whether the major antigens are matched or not
matched. The cost benefit and potential utility maymake these
the preferred choice for some PSC based therapy.
Overall it appears to us that each approachmay be uniquely
suited to certain disease indications. For cardiac transplant in
congestive cardiac failure or in pediatric malformations or for
bone defect repair sufficient time is available to obtain autol-
ogous cells, differentiate them and then transplant them. Lung,
gut, liver and spleen are generally thought to be more
immunogeneic and in acute disorders of such organs alloge-
neic therapy is unlikely to work but HLA matched cells with
immune suppression may be a viable choice. Likewise in
mongeneic diseases where gene editing is difficult but could
be standardized (such as replacing a whole exon rather than
correcting a point mutation) or using a safe harbor strategy one
can imagine that the economies of scale and time saving
would make banked types cells a cell of choice even in
diseases with a slow progression. Allogeneic therapy may be
an ideal cost effective solution where cells are required for
immune stimulation over a short time period or to provide
cells with a short life cycle or when cells are being
transplanted into immune privileged sites such as what has
being attempted in Parkinson`s disease [14, 15]. In the subse-
quent sections we review the process of immunematching, the
process of rejection and possible alternatives to a HLA bank.
Transplant Rejection and the Immune System
The rejection response to grafted tissue is caused by cell surface
molecules that induce an antigenic stimulus (see Table 1). The
immune system fully matures during early fetal development
and an immune response to self antigens is extinguished
through a careful processing step in the thymus and spleen.
This allows one to distinguish self-antigens from non-self and
is the basis for successful transplantation [16–19]. Thus deliv-
ery of cells prior to this maturation is successful even if no
matching is performed and even xenotransplants can be toler-
ated and tolerization strategies can be developed [20–24].
However, it is important to remember that only self-antigens
that are present at this stage are recognized as self. Embryonic
proteins that are not expressed at this stage will be rejected and
nuclear and cytoplasmic antigens that are not presented to the
thymus can still generate an immune response as is seen in
certain chronic diseases. These have important implications
when considering IPSC based therapy. IPSCsmay be immature
and even their differentiated products may express embryonic
antigens to which an immune response may be mounted.
Likewise it may be possible to treat individuals at an early stage
with allogeneic cells with immune suppression. Immunologists
Table 1 MHC based cell rejection. The table briefly summarizes the
issues related to cell transplants being rejected. The MHC systems is
primarily responsible for recognizing self vs non-self. However other
antigens and the innate immune system also contribute to rejection
The MHC system & foreign antigens
• MHC Class I by most cells in adult Including neural stem cells.
• Embryonic cells have little or none but will express them on
inflammation or differentiation
• MHC Class II by professional APC such as T cells, B cells,
macrophages, endothelial cells and thymic epithelial cells
•Different HLA antigens responsible for rejection at different time points.
HLA-DR mismatch important in the first 6 months, the HLA-B in the
first 2 years, and HLA- A mismatches over the long-term
• Foreign antigens are presented by cells expressing Class I or II peptides
on surface and lead to activation of T cells, B cells and macrophages.
• ABO blood groups and sex differences may have effects on transplants
• T–regs, Complement, atypical MHC antigens (HLA G), minor antigens
and modulators of local immune response (indoleamine, NO, etc.) can
exacerbate or inhibit rejection
• GVH (graft versus Host) immune issues may be important for blood
derivatives
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have also learnt that one can tolerize individuals to antigens so
that certain mismatches can be tolerated. Perhaps the best
example of this is tolerization to ABO mismatches in kidney
transplants [23, 24] (Table 2).
While there are exceptions as we have described above
nevertheless in the vast majority of cases when non-self tissue
is transplanted it evokes an immune response which is medi-
ated by a wide variety of transplantation antigens have been
described, including the MHCmolecules, minor histocompat-
ibility antigens, ABO blood group antigens, and monocytes/
endothelial cell antigens (Table 2). The minor histocompati-
bility antigens are processed peptides derived from cellular
antigens that are presented by MHC molecules but are not
derived from the MHC. ABO incompatibility can result in
hyperacute rejection of primarily vascularized grafts, such as
kidney and heart and could be an issue for IPSC derived
hematopoietic products [25–27]. Rejection is not always acute
but may be chronic and indeed different HLA antigens appear
to mediate different aspects of rejection Experience in trans-
plantation immunology has led to the realization that the
major impact in graft loss comes from the effects of HLA-B
and -DR antigens. There also appears to be a temporal HLA
mismatching effect. HLA-DR mismatch is most important in
the first 6 months after transplantation, the HLA-B effect
emerges in the first 2 years, and HLA-A mismatches have a
deleterious effect on long-term graft survival [28–30]. In
general a primary rejection response sensitizes the recipient
and the second exposure to the same antigen(s) results in a
greater, more rapid response that leads to rejection [31]. Cross
sensitization can occur as well and activation of the immune
system by non specific stimuli can override local inhibitory
effects and lead to rejection of otherwise tolerated mismatches
[32]. This is an important consideration when one considers
therapy that may require repeated transplants. It is also impor-
tant to note that different regions of the body show varying
degrees of rejection and in certain specialized instances (such
as pregnancy and cancer) mismatched alleles can be tolerated
[33].
An additional consideration that is of importance in trans-
plants related to the hematopoietic system is the issue of graft
versus host disease [34, 35]. Immune cells present in the
transplant can recognize recipient antigens as foreign and
activate an immune response by mobilizing host macrophages
and other effector cells.While this may not be relevant in most
PSC based therapy this will become of importance in delivery
of PSC derived cells of the hematopoietic lineage.
Thus PSC derived cells may provoke both an innate and
acquired immune response to embryonic antigens, foreign pro-
teins that are carried over from the culture system, minor HLA
antigen incompatibility, major HLA incompatibility and the
severity of the response depends on where the cells are
transplanted, the immune status of the individual and whether
the transplant is the first or one in a series of such transplants and
whether the individual has been cross sensitized by exposure to
other antigens. Rejection processes are similar to those of organs
and bone marrow though likely to be less severe (see below).
Immune Suppression Regimes after HLA Matching
While searching for an unrelated donor, high-resolution (4-
digit) genetic typing of both the patient and the donor is
necessary. The current standard of HLA typing has evolved
from bone marrow, cord blood and organ transplants is typing
at the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-
DQB1 genetic loci. An hematopoietic stem cell transplant
(HSCT)donor is referred to as a “10/10 allele match” or
“perfect match” when both HLA alleles are identical at each
of the HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-
DQB1 loci. A similar HLA matching model is used for organ
transplants [36–39].
It is important to understand that even with a perfect match
between unrelated donors minor histocompatibility antigens,
which are naturally processed peptides derived from normal
cellular proteins, may evoke a strong MHC-restricted re-
sponse because of the presence of different polymorphisms
in the donor and in the recipient (Tables 1 and 3). Likewise the
innate immune response may precipitate a reduction in func-
tion of the graft. Natural killer (NK) cells may also contribute
to alloreactivity, particularly in haploidentical HSCT, through
an interaction between killer immunoglobulin-like receptors
(KIRs) onNK cells and HLA class I alleles (particularly HLA-
Table 2 Reduced immunogenicity of cells. The table summarizes the
likely reasons cells may be less immunogenic than tissues or organs or
marrow. In bold we list the reasons why cell based therapy may be more
immunogenic. The pathways for rejection are summarized in the first
column to remind the non expert as to the different pathways that are
activated in rejection
Rejection PSC based cell transplant should be less
immunogenic
• ABO blood group
mediated
• Presumably no DC cells in most transplants
• Complement
mediated




• No ABO antigen response in most cases
• Innate immunity • IPSC/ESC cells may have some tolerance them-
selves and MSC and other stem cells maybe
immune modulatory
• Graft versus Host • No vasculature or complement mediated
rejection mechanisms
• Male vs. female •Other antigen presenting cells (support cells) may
not be present in the transplant
But: Fetal antigens may be present, Foreign protein may be present from
culture, atypical antigens may be formed, silenced genes expressed,
unknown therapeutic proteins may be present which may create rejection
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C) on mismatched cells. As a consequence of this biological
reality even in fully matched donations from unrelated donors
immune suppression regimes are considered necessary. In
bone marrow transplants these are done for a lifetime. It is
likewise considered necessary in transplants of highly
vascularized tissue such as liver, heart or pancreas. Indeed, it
was the breakthroughs in immune suppression such as cyclo-
sporine treatment, CTL antibodies and antithymoglobin
which allowed for the development of bone marrow and solid
organ transplants. The average cost of such immunotherapy is
approximately $20 K/year and the immune suppression ther-
apy has some morbidity as well [40]. Several investigators
have tired to eliminate or reduce the immune regimes 1–
2 years after transplant with mixed results [41, 42].
Initially there were concerns that iPSCs (and ESCs) unlike
other cells may be more immunogenic [43] than organs and
marrow and even other cells or that neoantigens may be
present [44, 45]. More recent work by Guha, Morizane and
others [46–48] provided data that autologous iPSC-derived
cells may not be more immunogenic. Indeed, It has been
shown that mouse ES cell-derived tissues display an inherent
capacity for immune privilege which permits the acceptance
of tissues across anMHC barrier without recourse to any form
of immune intervention [49, 50].
On the other hand, iPSCs, in contrary to ESCs, may have
residual information from the cell of origin, a phenomenon
known as epigenetic memory. The effects of epigenetic mem-
ory have just started to be explored. However, recent work
suggested that neurons derived from reprogrammed fibro-
blasts are more immunogenic than those derived from mesen-
chymal stromal cells [51]. It is also important to note that
epigenetic memory seems to be lost during successive pas-
sages in culture [52]. Irrespective of the functional relevance
of this phenomenon, we believe that this iPSC-specific issue
should not be overlooked without thorough discussion, in
particular in the case of iPSC-derived, clinical-grade cells to
be transplanted.
It is now thought that cell transplants will require less im-
mune suppression particularly for tissues that do not contain
MHC class I antigen presenting cells such as transplanting
neurons in the CNS. Likewise transplants with stem cells which
express low or no HLA antigens may require limited immune
suppression or where localized immune modulation is present
[53–55] Indeed, cells expressing no HLA antigens, obtained by
gene editing have been proposed as a future therapeutic alterna-
tive that can by-pass immune surveillance and therefore will
eliminate the need for immunosuppression. Recently, HLA-A
null cells have been obtained [56]. On the other hand,
transplanting cells that will not be recognized by the immune
system possesses intrinsic risks, that are currently being
discussed. Similarly transplants of the cornea, in transplants into
tissue where vascularity is limited, mismatched grafts appear to
be well tolerated and indeed the anterior chamber of the eye has
been used effectively as an immune privileged site even for
xenotransplants. The eye, like the brain is considered immune
privileged, owing to BBB properties as well as other active cell
mediated interactions known as anterior chamber-associated
immune deviation [ACAID]. Using cord blood cells has pro-
vided evidence that a 1 or 2 locus mismatch can be tolerated
from such cells [54, 55] and raised the hope that this may be the
case for other developmentally immature immature cells.
Transplants into the Central Nervous System
Besides the presence of the BBB, the immune response
in the central nervous system differs from other tissues
and organs mainly due to the absence of dendritic cells,
conventional lymphatics, the downregulation of major
histocompatibility complex (MHC) molecules within
Table 3 HLA typing and immune suppression. As discussed in the text
cells may be less immunogeneic than tissues or organs and this has raised
that possibility that with HLA matching no immune suppression will be
required. The argument for and against this are summarized. For a
detailed discussion the reader is directed to the references that discuss
these issues in detail
Will HLA typing allow us to eliminate use of immunosuppressants?
YES– Because No– Because
• Cells are less immunogenic than organs or tissue • But nevertheless cells are immunogenic
• Data that immune suppression can be removed • However in kidney and islets these data are controversial
• Data that fetal cells can tolerate some degree of
mismatch
• True but only limited mismatch tolerated
• Many target therapies are in immune privileged
sites
• However, blood and other non immune privileged sites being considered
• Embryonic cells have low or no MHC expression • Embryonic cells will elevate expression after transplantation and in cases of sensitization or
immune activation
• Cells may have localized immune modulatory
activity
• True but this may be overcome when homeostasis changes
If foreign protein expressed then immune suppression to that antigen will be required
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the CNS parenchyma, and the presence of local immu-
nosuppressive factors [57–59]. The immunomodulatory
effects of astrocytes in the CNS could further contribute
to the immune-privileged state [54]. To date, the main
areas of allogenic cellular therapeutic transplantation
strategies targeting brain and spinal cord disease or
injury have included human fetal dopaminergic cells
(Parkinson’s Disease (PD)), human fetal neural stem
cells (Pelizaeas Merzbacher disease (PMD), spinal cord
injury (SCI) and amyotrophic lateral sclerosis), and hu-
man ESC derived oligondendrocyte precursors (SCI). In
most cases a transient (60 days–12 months depending
on the study) immune suppression strategy has been
employed and graft persistence has been documented
up to 16 years post transplantation. Experience with
CNS cellular transplants has thus confirmed that the
immune response is modest and that this modest re-
sponse could be readily attenuated when immunosup-
pression was used during the initial period of surgical
breach of the BBB [60, 61]. These results largely con-
firmed the assumptions based on rodent syngenic, allo-
geneic and autologous transplants that had been per-
formed in the 1990’s [62] In addition, host immune
system monitoring has failed to detect graft directed
immune responses. Similar data with mismatched or
allogeneic MSC suggest that MSC while not immune
privileged are immunomodulatory and do not provoke a
large rejection response and in many instances can tamp
down a immune response [63–65].
While data for PSC-derived cell transplants in humans is
limited the results so far suggest that immune suppression is
likely required but may be less that what is necessary for organ
or marrow transplants (Table 2). Clinical trials using fetal tissue
transplantation into the brain of PD patients have used long-
term, short-term or no immunosuppression [66]. In some cases,
it has been argued that stopping immunosuppression had detri-
mental consequences to the survival, growth or function of the
transplanted cells [66]. In addition, inflammatory signals have
been shown to affect the survival, differentiation and prolifera-
tion of neural progenitor cells in animal models [67]. There-
fore, we would argue that one should be cautious in assuming
that no immune suppression will be required over the long term
as cells may begin to express immunogenic antigens or the
immune system begin to react to antigens present on these cells
in response to other insults or exposure to infections as may
occur years or decades after a transplant. Importantly, periph-
eral, sustained inflammation can modulate brain inflammation
and exacerbate neurodegeneration in the substantia nigra in
animal models, increasing the complexity of the analysis of
the possible consequences of immunomodulation on PD pro-
gression [68]. In summary despite the evidence that cells them-
selves may be less immunogenic than solid organs and bone
marrow it is also clear that transplanted cells can be rejected and
thus one would prefer using HLA matched cells rather than
mismatched cells should such cells be available. iPSC technol-
ogy allows one to consider creating such a bank and several
issue related to generating such a bank are under active discus-
sion. In the next section we summarize some of the consider-
ations in developing such a bank.
Size of Bank and its Creation
HLA are highly polymorphic, and gene sequencing analysis
and more than 2558 HLA class I and II alleles have been
recognized. This variability would suggest that the number of
lines required would be a daunting task. However, HLA anti-
gens are inherited in a Mendelian dominant manner. HLA
genes are almost always inherited together, thus the antigens
of the entire HLA region inherited from one parent collectively
are called haplotype. In humans, these genes reside in the short
arm of chromosome 6. Because chromosome 6 is an autosome
(a chromosome with two pairs), all individuals have two HLA
haplotypes (one for each chromosome). According to this, any
sibling pair has a 25 % chance of inheriting the same two
parental haplotypes, a 50 % chance of sharing one haplotype,
and a 25 % chance of having two completely different haplo-
types. All children are haploidentical with each parent. Based
on these facts several empirical calculations can be made based
on frequency, ethnic diversity and the type of therapy that will
be required. Several groups have performed such calculations
[69–76]. According to one estimate, an iPSC bank from 150
selected homozygous HLA-typed volunteers could match 93%
of the United Kingdom population with a minimal requirement
for immunosuppression [74]. Similarly, as few as 50 such lines
could potentially match 90% of the Japanese population [69].
A similar limited number of lines may be sufficient for Korea
and the Han population in China and perhaps Argentina (77–81
and references therein and C. Gamba, personal communica-
tion). However, more diverse populations will require more
lines as would be expected for Brazil, US and India (81 and
references therein). The data therefore suggest that creation of a
“haplobank” of iPSC lines homozygous for a range of HLA
types representative of different geographical populations and
ethnic groups could simplify HLA matching, provide matches
for a reasonable percentage of a target population, and extend
iPSC-derived therapies beyond the autologous setting.
Although only a limited number of lines are required it will
be critical to identify the right donor to generate lines that
carries the representative Haplotype. Thus one needs a source
of clinically compliant tissue sample which is typed for HLA
and access to the data set to select individual donors that are
most representative as contributors to a bank. The steps an
issues that need to be considered are summarized in Fig. 1. Of
the various questions perhaps the most important one is what
starting sample to use and how one may harmonize collection
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and storage and distribution of lines across the world. These
issues and concerns are being debated currently and the reader
is directed to those articles for a detailed discussion [82, 83].
Strategies to Extend the Utility of a Haplobank
Although banking of HLA matched samples is one possible
solution to resolving immune issues there are several other
potential strategies that have been considered. We describe
some of them and suggest that application of these strategies
can complement the Haplobank approach and in some cases
may render the use of immune matched cells unnecessary.
Some of these approaches are summarized in Table 4.
Perhaps the simplest approach based on findings describe
above with transplants of fetal cells is to consider localized
immune suppression. Successful local suppression with long
term engraftment has been described and is based on
the pathways that enable a mismatched fetus to survive for
prolonged periods as a transplant with a shared circulation.
These include molecules such as indolemine, nitric oxide
synthase and prostaglandins that modulate macrophage and
microglial behavior [84]. More recently it has been suggested
that some stem cells possess such localized immune modula-
tory activity and cells such as mesenchymal stem cells (MSC)
especially placental derivedMSCmay have a capability along
these lines. Therapy may then consist of co-transplantation of
the functionally required type with mixed with MSC or cells
engineered to express localized immune modualtory genes
(see references above).
Several other strategies have been proposed [85–95]. One
solution is to take advantage of the pluripotency of iPSCs to
generate not only therapeutic cells but also immature cells of
the immune system such as dendritic cells expressing
neoantigens to which tolerance is required [88] . Another
critical area of investigation into strategies to induce donor-
specific tolerance is rejuvenation of the thymus [89–91]. The
thymus is the main organ responsible for establishing immune
tolerance via elimination of autoreactive T cells. iPSCs could
be used as a replacement thymic epithelial cells (TECs) that
Fig. 1 Making iPSC banks. A
flowchart of the IPSC banking
process is provided. Note that
three types of data bases will be
required and that there are
important decisions that need to
bemade at each step. No clarity or
previous guidance from the
regulatory authorities exist.
Decisions will need to be made
early to avoid the cost of
recreating banks which have the
potential of lasting over decades
Table 4 Additional ways to modulate the immune system. The table
summarizes the various strategies that have been proposed to reduce or
eliminate a immune rejection of cells. Some of these strategies are only
possible with pluripotent cells and some require extensive gene
engineering. For detail see text and references
Ensuring survival of transplanted cells
• Autologous or Syngeneic transplant
• Transplant in utero
• Transplant to an immune privileged site
• Co-transplant of immune modulatory cells
• Localized immunesuppression (Indoleamine, NO, HLA-G)
• CTL blockade, anti-TCR therapy
• ABO tolerization and other antigen tolerization
• T-regs- (CD24-) to induce tolerization
• Mixed chimerism with accompanied bone marrow transplant
• iPSC engineering
• Generation of DC cells
• Thymic rejuvenation
• HLA matching with immune suppression
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could be used to induce tolerance to an iPSC-derived graft.
Two recent studies describe progress in generating TECs from
human PSCs, although work remains to be done improve their
maturity and functionality [89–91]. Other approaches include
development of immune-privileged PSC derivatives capable
of blocking the activation of co-stimulatory receptors respon-
sible for immune recognition. This could be accomplished by
genetic “knock-in” of ligands of potent inhibitory receptors
expressed by T cells (e.g. CTLA4 or PD-1) or by targeting
inhibitory pathways that mediate immunosuppression (e.g.
indoleamine 2,3-dioxyge-nase or HLA-G) [92–94]. Likewise
monoclonal antibodies could be used. For example Pearl et al.
[86] showed that monoclonal antibody-mediated co-stimula-
tion/adhesion blockade of host T cells can result in long-term
engraftment of hESC and human iPSC grafts in murine
models.
Thus the haplobank could serve not only as a source of
partially immune matched cells but could also be as a source
of transplants of mismatched cells by permitting the standard-
ized generation of tolerization inducing cells such as dendritic
cells or thymic epithelial cells. Likewise having a bank of well
characterized cells with appropriate patient history collected in
a clinically compliant fashion would allow gene engineering
to effectively modulate an immune response (56). Such gene
engineering strategies have been shown to be efficient and
reliable (56). The utility of the bank could thus be further
extended and the use of long term immunosupressive drugs
could be further reduced.
Summary
Several strategies can be utilized to overcome the rejection of
mismatched cells. At one extreme one can generate autolo-
gous cells and on the other one can use mismatched cells that
have been modified or are co-transplanted with reagents that
allow such cells to bypass the rejection phenomenon.. A
intermediate approach is to reduce the rejection possibility
by using HLA matched cells followed by limited immuno-
suppression as dictated by the cell type delivered and the host
immune status. No solution seems to be clearly superior over
another and cost, regulations and scientific breakthroughs will
determine which strategy will be the strategy of choice in the
future. iPSC clearly have the potential to reduce the cost of
cell based therapy and likely will play an important role in an
future approach to personalized medicine.
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